ArticleFrontiers in immunology2026
Systemic immune remodeling following curative (R0) resection of colorectal liver metastases.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer liver metastases (CRLM) are a key driver of systemic immunosuppression and a determinant of poor prognosis. While surgical resection remains the mainstay of treatment, the dynamics of the immune landscape post-resection remain insufficiently characterized. This study aims to delineate immune reprogramming following liver resection in CRLM patients, offering insights into potential therapeutic strategies. Methods: Peripheral blood samples were collected from CRLM patients before and after liver resection. Peripheral blood mononuclear cells were analyzed using multiparameter flow cytometry with adaptive and innate immunity panels, processed with FlowJo and FlowAI. Tumor immune microenvironment (TIME) was assessed by H&E, immunohistochemistry, and immunofluorescence. Results: Postoperative analysis revealed remodeling of T cell composition, with a significant increased proportion of CD4+ T cells among circulating CD3+ T cells, including the CD28+ CD4+ subset, while regulatory T cells and T follicular helper cells remained unchanged. Overall proportion of CD8+ T cells among circulating CD3+ T cells was reduced. Among immune checkpoint-associated populations, the percentage of TIM3+ CD4+ T cells decreased significantly, whereas PD-1+ CD4+ T cells and exhausted PD-1+ TIM3+ double-positive T-cell subsets showed modest downward trends. Innate immune populations remained largely unchanged. Patients who experienced recurrence had higher postoperative proportion of S100A9+ monocytic myeloid-derived suppressor cells (M-MDSCs). Exploratory analyses further suggested that KRAS-mutated tumors may be associated with distinct postoperative immune profiles. Conclusions: Liver metastasis resection is associated with CD4+ T cell-dominant systemic immune remodeling and changes in exhaustion-associated markers, hypothetically suggesting a potential postoperative window for future immunotherapeutic interventions. Although highly speculative and requiring further functional validation, these findings suggest that the altered CD4+ T cell landscape warrants further investigation regarding its potential relevance to adoptive cellular therapies or immune checkpoint inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.